Integrated substance use and prenatal care delivery in the era of COVID-19.
J Subst Abuse Treat
; 124: 108273, 2021 05.
Article
in English
| MEDLINE | ID: covidwho-1002833
ABSTRACT
The COVID-19 pandemic has directly impacted integrated substance use and prenatal care delivery in the United States and has driven a rapid transformation from in-person prenatal care to a hybrid telemedicine care model. Additionally, changes in regulations for take home dosing for methadone treatment for opioid use disorder due to COVID-19 have impacted pregnant and postpartum women. We review the literature on prenatal care models and discuss our experience with integrated substance use and prenatal care delivery during COVID-19 at New England's largest safety net hospital and national leader in substance use care. In our patient-centered medical home for pregnant and postpartum patients with substance use disorder, patients' early responses to these changes have been overwhelmingly positive. Should clinicians continue to use these models, thoughtful planning and further research will be necessary to ensure equitable access to the benefits of telemedicine and take home dosing for all pregnant and postpartum patients with substance use disorder.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Prenatal Care
/
Telemedicine
/
Delivery of Health Care, Integrated
/
COVID-19
/
Opioid-Related Disorders
Limits:
Female
/
Humans
/
Pregnancy
Country/Region as subject:
North America
Language:
English
Journal:
J Subst Abuse Treat
Journal subject:
Substance-Related Disorders
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS